Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.72 |
| ▸ | OPRM1 | P35372 | 5/20 | 0.71 |
| ▸ | SIGMAR1 | Q99720 | 4/20 | 0.62 |
| ▸ | GRIN2D | O15399 | 7/20 | 0.61 |
| ▸ | GRIN3B | O60391 | 7/20 | 0.61 |
| ▸ | GRIN1 | Q05586 | 7/20 | 0.61 |
| ▸ | GRIN2A | Q12879 | 7/20 | 0.61 |
| ▸ | GRIN2B | Q13224 | 7/20 | 0.61 |
| ▸ | GRIN2C | Q14957 | 7/20 | 0.61 |
| ▸ | GRIN3A | Q8TCU5 | 7/20 | 0.61 |
| ▸ | SLC6A4 | P31645 | 4/20 | 0.61 |
| ▸ | MRGPRX2 | Q96LB1 | 4/20 | 0.61 |
| ▸ | CYP2D6 | P10635 | 4/20 | 0.61 |
| ▸ | SLC22A1 | O15245 | 3/20 | 0.61 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.61 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.61 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.61 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.61 |
| ▸ | TSHR | P16473 | 1/20 | 0.61 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18229424 | 1.00 | GAA (0.72) | GAAOPRM1SIGMAR1GRIN2DGRIN3B | |
| SCHEMBL24538638 | 1.00 | GAA (0.72) | GAAOPRM1SIGMAR1GRIN2DGRIN3B | |
| SCHEMBL19199626 | 1.00 | GAA (0.72) | GAAOPRM1SIGMAR1GRIN2DGRIN3B | |
| SCHEMBL24538514 | 0.88 | OPRM1 (0.82) | GAAOPRM1SIGMAR1GRIN2DGRIN3B | |
| SCHEMBL24368178 | 0.87 | GAA (0.59) | GAAOPRM1SIGMAR1GRIN2DGRIN3B | |
| SCHEMBL20901591 | 0.87 | GAA (0.59) | GAAOPRM1SIGMAR1GRIN2DGRIN3B | |
| SCHEMBL24796501 | 0.87 | SIGMAR1 (0.82) | GAAOPRM1SIGMAR1GRIN2DGRIN3B | |
| SCHEMBL20901568 | 0.86 | OPRM1 (0.69) | OPRM1SIGMAR1GRIN2DGRIN3BGRIN1 | |
| SCHEMBL13181329 | 0.86 | GAA (0.71) | GAAOPRM1SIGMAR1GRIN2DGRIN3B | |
| SCHEMBL10989086 | 0.85 | OPRM1 (0.69) | OPRM1SIGMAR1GRIN2DGRIN3BGRIN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230158017-A1 | METHODS FOR TREATING DEPRESSIVE SYMPTOMS | JPMORGAN CHASE BANK, N.A. AS ADMINISTRATIVE AGENT | 2023-05-25 | — | — | US | disclosed |
| US-20230158017-A1 | METHODS FOR TREATING DEPRESSIVE SYMPTOMS | JPMORGAN CHASE BANK, N.A. AS ADMINISTRATIVE AGENT | 2023-05-25 | — | — | US | disclosed |
| US-11534436-B2 | Methods for treating depressive symptoms | ALKERMES PHARMA IRELAND LIMITED (IE) | 2022-12-27 | — | — | US | disclosed |
| US-11534436-B2 | Methods for treating depressive symptoms | ALKERMES PHARMA IRELAND LIMITED (IE) | 2022-12-27 | — | — | US | disclosed |
| US-20210000818-A1 | METHODS FOR TREATING DEPRESSIVE SYMPTOMS | JPMORGAN CHASE BANK, N.A. AS ADMINISTRATIVE AGENT | 2021-01-07 | — | — | US | disclosed |
| US-20210000818-A1 | METHODS FOR TREATING DEPRESSIVE SYMPTOMS | JPMORGAN CHASE BANK, N.A. AS ADMINISTRATIVE AGENT | 2021-01-07 | — | — | US | disclosed |
| US-10752592-B2 | Morphan and morphinan analogues, and methods of use | ALKERMES PHARMA IRELAND LIMITED (IE) | 2020-08-25 | — | — | US | disclosed |
| US-10736890-B2 | Methods for treating depressive symptoms | ALKERMES PHARMA IRELAND LIMITED (IE) | 2020-08-11 | — | — | US | disclosed |
| EP-3004114-B1 | MORPHAN AND MORPHINAN ANALOGUES, AND METHODS OF USE | ALKERMES PHARMA IRELAND LTD (IE) | 2019-12-25 | — | — | EP | disclosed |
| US-20190218185-A1 | Morphan And Morphinan Analogues, And Methods Of Use | JPMORGAN CHASE BANK, N.A. AS ADMINISTRATIVE AGENT | 2019-07-18 | — | — | US | disclosed |
| US-20160326119-A1 | MORPHAN AND MORPHINAN ANALOGUES, AND METHODS OF USE | JPMORGAN CHASE BANK, N.A. AS ADMINISTRATIVE AGENT | 2016-11-10 | — | — | US | disclosed |
| US-20160326119-A1 | MORPHAN AND MORPHINAN ANALOGUES, AND METHODS OF USE | JPMORGAN CHASE BANK, N.A. AS ADMINISTRATIVE AGENT | 2016-11-10 | — | — | US | disclosed |
| US-9416137-B2 | Morphan and morphinan analogues, and methods of use | ALKERMES PHARMA IRELAND LIMITED (IE) | 2016-08-16 | — | — | US | disclosed |
| US-20150376197-A1 | MORPHAN AND MORPHINAN ANALOGUES, AND METHODS OF USE | JPMORGAN CHASE BANK, N.A. AS ADMINISTRATIVE AGENT | 2015-12-31 | — | — | US | disclosed |
| US-9133125-B2 | Morphan and morphinan analogues, and methods of use | ALKERMES PHARMA IRELAND LIMITED (IE) | 2015-09-15 | — | — | US | disclosed |
| US-9133125-B2 | Morphan and morphinan analogues, and methods of use | ALKERMES PHARMA IRELAND LIMITED (IE) | 2015-09-15 | — | — | US | disclosed |
| US-20150072971-A1 | Methods for Treating Depressive Symptoms | ALKERMES PHARMA IRELAND LIMITED (IE) | 2015-03-12 | — | — | US | disclosed |
| US-20150072971-A1 | Methods for Treating Depressive Symptoms | ALKERMES PHARMA IRELAND LIMITED (IE) | 2015-03-12 | — | — | US | disclosed |
| US-20150045384-A1 | Morphan and Morphinan Analogues, and Methods of Use | ALKERMES PHARMA IRELAND LIMITED (IE) | 2015-02-12 | — | — | US | disclosed |
| US-20150045384-A1 | Morphan and Morphinan Analogues, and Methods of Use | ALKERMES PHARMA IRELAND LIMITED (IE) | 2015-02-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210000818-A1 | METHODS FOR TREATING DEPRESSIVE SYMPTOMS | OPRM1, OPRL1, OPRK1 | GAA 1347/4885OPRM1 1/4885SIGMAR1 6/4885 |
| US-20150072971-A1 | Methods for Treating Depressive Symptoms | OPRM1, OPRL1, OPRK1 | GAA 1347/4885OPRM1 1/4885SIGMAR1 6/4885 |
| US-20230158017-A1 | METHODS FOR TREATING DEPRESSIVE SYMPTOMS | OPRM1, OPRL1, OPRK1 | GAA 1347/4885OPRM1 1/4885SIGMAR1 6/4885 |
| US-20150376197-A1 | MORPHAN AND MORPHINAN ANALOGUES, AND METHODS OF USE | MTPN, UTRN, FSCN1 | GAA 398/4885OPRM1 159/4885SIGMAR1 1138/4885 |
| US-11534436-B2 | Methods for treating depressive symptoms | OPRM1, OPRL1, OPRK1 | GAA 1347/4885OPRM1 1/4885SIGMAR1 6/4885 |
| US-20150045384-A1 | Morphan and Morphinan Analogues, and Methods of Use | MTPN, UTRN, FSCN1 | GAA 398/4885OPRM1 159/4885SIGMAR1 1138/4885 |
| US-20160326119-A1 | MORPHAN AND MORPHINAN ANALOGUES, AND METHODS OF USE | MTPN, UTRN, FSCN1 | GAA 398/4885OPRM1 159/4885SIGMAR1 1138/4885 |
| US-10736890-B2 | Methods for treating depressive symptoms | OPRM1, OPRL1, OPRK1 | GAA 1347/4885OPRM1 1/4885SIGMAR1 6/4885 |
| US-10752592-B2 | Morphan and morphinan analogues, and methods of use | MTPN, UTRN, FSCN1 | GAA 398/4885OPRM1 159/4885SIGMAR1 1138/4885 |
| US-20190218185-A1 | Morphan And Morphinan Analogues, And Methods Of Use | MTPN, UTRN, FSCN1 | GAA 398/4885OPRM1 159/4885SIGMAR1 1138/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.